Search research articles
Contact Us
Filters
Showing results (31-40 of 457) with videos related to
Page
of 46
Sort By:
The New England Journal of Medicine
|
December 14, 2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply
Carolyn T Bramante, John B Buse, David R Boulware
Diabetes Care
|
June 27, 2018
Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?
John B Buse, David A D'Alessio, Matthew C Riddle
Pediatrics
|
August 2, 2018
Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet: A Word of Caution
Elizabeth J Mayer-Davis, Lori M Laffel, John B Buse
The New England Journal of Medicine
|
November 25, 2017
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F E Mann, David D Ørsted, John B Buse
The Lancet. Diabetes & Endocrinology
|
September 18, 2020
Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?
Kamlesh Khunti, Melanie J Davies, Nikolaus Marx, et al.
Current Medical Research and Opinion
|
September 26, 2007
A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes
Kathleen M Dungan, Tia Guster, Darren A DeWalt, et al.
Diabetes Technology & Therapeutics
|
August 22, 2018
Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
Satish K Garg, Anne L Peters, John B Buse, et al.
Journal of Neurophysiology
|
September 1, 2021
Causal role of frontal-midline theta in cognitive effort: a pilot study
Amber McFerren, Justin Riddle, Christopher Walker, et al.
Diabetes Care
|
February 20, 2026
Response to comment on Buse et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 2025;48:2012-2020
John B Buse, Steven E Kahn, Tina K Schlafly, et al.
American Journal of Nephrology
|
March 16, 2020
Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results
Matthew R Weir, Peter A McCullough, John B Buse, et al.
Page
of 46
Search research articles
Search
Showing results (31-40 of 457) with videos related to
Sort By:
Page
of 46
The New England Journal of Medicine
|
December 14, 2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply
Carolyn T Bramante, John B Buse, David R Boulware
Diabetes Care
|
June 27, 2018
Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?
John B Buse, David A D'Alessio, Matthew C Riddle
Pediatrics
|
August 2, 2018
Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet: A Word of Caution
Elizabeth J Mayer-Davis, Lori M Laffel, John B Buse
The New England Journal of Medicine
|
November 25, 2017
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F E Mann, David D Ørsted, John B Buse
The Lancet. Diabetes & Endocrinology
|
September 18, 2020
Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?
Kamlesh Khunti, Melanie J Davies, Nikolaus Marx, et al.
Current Medical Research and Opinion
|
September 26, 2007
A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes
Kathleen M Dungan, Tia Guster, Darren A DeWalt, et al.
Diabetes Technology & Therapeutics
|
August 22, 2018
Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
Satish K Garg, Anne L Peters, John B Buse, et al.
Journal of Neurophysiology
|
September 1, 2021
Causal role of frontal-midline theta in cognitive effort: a pilot study
Amber McFerren, Justin Riddle, Christopher Walker, et al.
Diabetes Care
|
February 20, 2026
Response to comment on Buse et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 2025;48:2012-2020
John B Buse, Steven E Kahn, Tina K Schlafly, et al.
American Journal of Nephrology
|
March 16, 2020
Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results
Matthew R Weir, Peter A McCullough, John B Buse, et al.
Page
of 46